These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8171747)

  • 1. Down regulation of Qa gene expression on drug-modified tumor cells.
    Leroy E; Lattuada D; Casnici C; Franco P; Marelli OE
    Tumori; 1993 Dec; 79(6):439-43. PubMed ID: 8171747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional studies of H-2k-like epitopes on DTIC treated and untreated L1210 (H-2d) clones.
    Marelli OE; Franco P; Labeta MO; Festenstein H
    J Immunogenet; 1989; 16(4-5):373-80. PubMed ID: 2639909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DTIC xenogenized lines obtained from an L1210 clone: clonal analysis of cytotoxic T lymphocyte reactivity.
    Marelli O; Franco P; Canti G; Ricci L; Prandoni N; Nicolin A; Festenstein H
    Br J Cancer; 1988 Aug; 58(2):171-5. PubMed ID: 2458749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro generation of a highly immunogenic subline of L1210 leukemia following exposure to 5-(3,3'-dimethyl-1-triazeno)imidazole-4-carboxamide.
    Contessa AR; Bonmassar A; Giampietri A; Circolo A; Goldin A; Fioretti MC
    Cancer Res; 1981 Jun; 41(6):2476-82. PubMed ID: 7016315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibodies to the L1210 murine leukemia cell line and to a drug-altered subline.
    Testorelli C; Archetti YL; Aresca P; Del Vecchio L
    Cancer Res; 1985 Nov; 45(11 Pt 1):5299-303. PubMed ID: 4053006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L1210/DTIC antigenic subline: studies at the clone level.
    Marelli O; Canti G; Franco P; Prandoni N; Ricci L; Nicolin A
    Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1401-5. PubMed ID: 2435557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive immunity in mice challenged with L1210/DTIC clones.
    Canti G; Ricci L; Marelli O; Franco P; Nicolin A
    Cancer Immunol Immunother; 1987; 24(1):64-7. PubMed ID: 3545466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of new antigenic properties on DTIC-treated L1210 clones.
    Marelli O; Franco P; Canti G; Prandoni N; Ricci L
    Tumori; 1988 Aug; 74(4):387-92. PubMed ID: 3263723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination of leukemic mice with viable drug-altered leukemic cells.
    Boerio D; Cavalli M; Marelli O; Veronese F; Nicolin A
    Ric Clin Lab; 1978; 8(3):127-33. PubMed ID: 746293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy and immunotherapy of L1210 leukemic mice with antigenic tumor sublines.
    Nicolin A; Canti G; Marelli O; Veronese F; Goldin A
    Cancer Res; 1981 Apr; 41(4):1358-62. PubMed ID: 7011535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy.
    Giampietri A; Bonmassar A; Puccetti P; Circolo A; Goldin A; Bonmassar E
    Cancer Res; 1981 Feb; 41(2):681-7. PubMed ID: 7448813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro generation of primary cytotoxic lymphocytes against L5178Y leukemia antigenically altered by 5-(3,3'-dimethyl-1-triazeno)-imidazole-4-carboxamide in vivo.
    Romani L; Fioretti MC; Bonmassar E
    Transplantation; 1979 Sep; 28(3):218-22. PubMed ID: 494379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro lymphocyte stimulation and the generation of cytotoxic lymphocytes with drug-induced antigenic lymphomas.
    Testorelli C; Franco P; Goldin A; Nicolin A
    Cancer Res; 1978 Mar; 38(3):830-4. PubMed ID: 75062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two antiemetic regimens do not impair chemical xenogenization induced in vivo by 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide.
    Ballerini P; Franchi A; Fuschiotti P; Piccioni D; Bonmassar E
    Cancer Chemother Pharmacol; 1989; 24(6):359-62. PubMed ID: 2791188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological cross-reactivity between H-2Dk product and DTIC-treated H-2d lymphoma.
    Marelli O; Testorelli C; Canti G; Festenstein H; Nicolin A
    J Immunogenet; 1982 Dec; 9(6):407-12. PubMed ID: 6186748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased immunogenicity of murine lymphoma cells following exposure to gamma rays in vivo.
    Guadagni F; Roselli M; Fuggetta MP; Perno CF; Goldin A; Giuliani A
    Chemioterapia; 1984 Dec; 3(6):358-64. PubMed ID: 6529777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA alkylating agents alleviate silencing of class II transactivator gene expression in L1210 lymphoma cells.
    Murphy SP; Holtz R; Lewandowski N; Tomasi TB; Fuji H
    J Immunol; 2002 Sep; 169(6):3085-93. PubMed ID: 12218125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibody-recognizing tumor-associated antigen of DBA/2 mouse lymphoma L1210 and its sublines.
    Fuji H
    Transplant Proc; 1980 Sep; 12(3):388-90. PubMed ID: 6784299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clonal variation in tumorigenicity of L1210 lymphoma cells: nontumorigenic variants with an enhanced expression of tumor-associated antigen and Ia antigens.
    Fuji H; Iribe H
    Cancer Res; 1986 Nov; 46(11):5541-7. PubMed ID: 3489524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic cross-reactivity of antigen(s) induced by drug treatment in two leukemic sublines.
    Nicolin A; Bini A; Di Padova F; Goldin A
    J Immunol; 1976 May; 116(5):1347-9. PubMed ID: 58028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.